

RECEIVED
CENTRAL FAX CENTER**NOV 27 2006**

GlaxoSmithKline

FAX**To** Group 2176**Company** USPTO**Fax** (571) 273-8300**From** Patty Wilson**Tel** 1-919-483-1007; Facsimile: 1-919-483-7977**E-mail** patricia.t.wilson@gsk.com**Date** November 27, 2006 **Pages including cover** 3**Subject** Application of: Lawrence
U.S. Serial No.: 10/570,229
Attorney Docket No. PR60476USwGlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709Tel: 919 483 2100
www.gsk.com**Attached:** Second Preliminary Amendment**Certificate of Transmission by Facsimile (37 CFR 1.8)**I hereby certify that this correspondence is being facsimile
transmitted on November 27, 2006.A handwritten signature in dark ink, appearing to read "Patty Wilson", is written over a horizontal line.
Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

RECEIVED
CENTRAL FAX CENTER
NOV 27 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ronald Maxwell LAWRENCE
International App. No.: PCT/EP2004/009819
International Filing Date: September 2, 2004
Title: *PROCESS FOR THE PREPARATION OF (1S, 4R)-CIS-4-
[2-AMINO-6-CHLORO-9H-PURIN-9-YL]-2-
CYCLOPENTENE-1-METHANOL*

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND PRELIMINARY AMENDMENT

Sir:

The above-identified application is being transmitted herewith for entry in the United States National Phase under Chapter II of the PCT for the purposes of adding priority information.

Prior to examination on the merits, please amend the application as follows:

Amendments to the Specification begin on page 2.

Remarks begin on page 3.